Skip to main content

Table 2 Comparison of the incidence of key drug-related grade ≥3 AEs at final follow-up

From: Nivolumab plus ipilimumab versus nivolumab in individuals with treatment-naive programmed death-ligand 1 positive metastatic soft tissue sarcomas: a multicentre retrospective study

Event, n (%) NPI (n=74) NIV (n=76) p-value
Anaemia 9 (12.2) 8 (10.5) 0.752
Aspartate aminotransferase increased 5 (6.8) 0 (0.0) 0.021a
Colonic perforation 0 (0.0) 1 (1.3) 1.000
Creatinine increased 2 (2.7) 2 (2.6) 0.978
Dehydration 3 (4.1) 1 (1.3) 0.298
Dyspnoea 6 (8.1) 0 (0.0) 0.011a
Hyponatraemia 9 (12.2) 1 (1.3) 0.008a
Hypotension 8 (10.8) 0 (0.0) 0.003a
Vaginal fistula 3 (4.1) 0 (0.0) 0.076
Lipases increased 4 (5.4) 4 (5.3) 0.969
Lung infection 3 (4.1) 3 (3.9) 0.973
Nausea 4 (5.4) 2 (2.6) 0.386
Nervous system disorders 8 (10.8) 1 (1.3) 0.014a
Skin infection 3 (4.1) 0 (0.0) 0.076
Urinary tract infection 4 (5.4) 0 (0.0) 0.040a
≥ 2 AEs in one patient 23 (31.1) 12 (15.8) 0.027a
  1. aStatistically significant. AEs adverse events, NPI nivolumab plus ipilimumab, NIV nivolumab